Aim immunotech provides update on jorgl activist group litigation

Ocala, fla.--(business wire)--aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the delaware court of chancery concerning a motion for a temporary restraining order (“tro”) sought by activist shareholder jonathan jorgl: “this morning we announced in a
AIM Ratings Summary
AIM Quant Ranking